Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium
- PMID: 20047977
- PMCID: PMC2842204
- DOI: 10.1093/aje/kwp383
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium
Abstract
In an International Lymphoma Epidemiology Consortium pooled analysis, polymorphisms in 2 immune-system-related genes, tumor necrosis factor (TNF) and interleukin-10 (IL10), were associated with non-Hodgkin lymphoma (NHL) risk. Here, 8,847 participants were added to previous data (patients diagnosed from 1989 to 2005 in 14 case-control studies; 7,999 cases, 8,452 controls) for testing of polymorphisms in the TNF -308G>A (rs1800629), lymphotoxin-alpha (LTA) 252A>G (rs909253), IL10 -3575T>A (rs1800890, rs1800896), and nucleotide-binding oligomerization domain containing 2 (NOD2) 3020insC (rs2066847) genes. Odds ratios were estimated for non-Hispanic whites and several ethnic subgroups using 2-sided tests. Consistent with previous findings, odds ratios were increased for "new" participant TNF -308A carriers (NHL: per-allele odds ratio (OR(allelic)) = 1.10, P(trend) = 0.001; diffuse large B-cell lymphoma (DLBCL): OR(allelic) = 1.23, P(trend) = 0.004). In the combined population, odds ratios were increased for TNF -308A carriers (NHL: OR(allelic) = 1.13, P(trend) = 0.0001; DLBCL: OR(allelic) = 1.25, P(trend) = 3.7 x 10(-6); marginal zone lymphoma: OR(allelic) = 1.35, P(trend) = 0.004) and LTA 252G carriers (DLBCL: OR(allelic) = 1.12, P(trend) = 0.006; mycosis fungoides: OR(allelic) = 1.44, P(trend) = 0.015). The LTA 252A>G/TNF -308G>A haplotype containing the LTA/TNF variant alleles was strongly associated with DLBCL (P = 2.9 x 10(-8)). Results suggested associations between IL10 -3575T>A and DLBCL (P(trend) = 0.02) and IL10 -1082A>G and mantle cell lymphoma (P(trend) = 0.04). These findings strengthen previous results for DLBCL and the LTA 252A>G/TNF -308A locus and provide robust evidence that these TNF/LTA gene variants, or others in linkage disequilibrium, are involved in NHL etiology.
Figures
Comment in
-
Is a TNF alpha polymorphism responsible for mutations in the TP53 gene?Scand J Immunol. 2011 Feb;73(2):154-5. doi: 10.1111/j.1365-3083.2010.02487.x. Scand J Immunol. 2011. PMID: 21198757 No abstract available.
References
-
- Altieri A, Bermejo JL, Hemminki K. Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. Blood. 2005;106(2):668–672. - PubMed
-
- Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159–2169. - PubMed
-
- Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354(23):2431–2442. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA62006/CA/NCI NIH HHS/United States
- CA89745/CA/NCI NIH HHS/United States
- P42 ES004705/ES/NIEHS NIH HHS/United States
- CA92153/CA/NCI NIH HHS/United States
- R01 CA092153/CA/NCI NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- R01 CA087014/CA/NCI NIH HHS/United States
- CA104862/CA/NCI NIH HHS/United States
- R03 CA089745/CA/NCI NIH HHS/United States
- CA87014/CA/NCI NIH HHS/United States
- R01 CA122663/CA/NCI NIH HHS/United States
- R01 CA104682/CA/NCI NIH HHS/United States
- 86528/CAPMC/ CIHR/Canada
- N01 CO012400/CA/NCI NIH HHS/United States
- 93100/CAPMC/ CIHR/Canada
- R01 CA045614/CA/NCI NIH HHS/United States
